Global Companion Diagnostics Market Report 2022: Increasing Clinical Trials and Need for Next-Generation Sequencing to Drive Sector
07 nov. 2022 08h53 HE
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Companion Diagnostics Market, By Product and Service, By Technology & By Region- Forecast and Analysis 2022-28" report has been added to ...
Companion Diagnostics Global Market to Reach $9.99 Billion by 2026 at a CAGR of 18.01%
29 sept. 2022 08h23 HE
|
Research and Markets
Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The "Companion Diagnostics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global companion diagnostics market...
Global Hospital-Acquired Infection Diagnostics Market Report 2022-2028: Increasing Awareness among Healthcare Institutions Driving Growth
08 août 2022 04h08 HE
|
Research and Markets
Dublin, Aug. 08, 2022 (GLOBE NEWSWIRE) -- The "Global Hospital-Acquired Infection Diagnostics Market Size, Share & Industry Trends Analysis Report By Product, By Infection Type, By Application,...
The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035, claims Roots Analysis
26 juil. 2022 09h15 HE
|
Roots Analysis
London, July 26, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. ...
Companion Diagnostics Market to Enjoy Advancements in AI, Big Data, NGS and Surpass the Value of 15 billion by 2028
21 juil. 2022 08h56 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, July 21, 2022 (GLOBE NEWSWIRE) -- The term “companion diagnostic” (CDx) is used to describe in vitro diagnostic devices (IVDs) that are essential for the safe and effective use of...
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
28 juin 2022 08h05 HE
|
Akoya Biosciences, Inc.
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted...
Global Minimal Residual Disease (MRD) Testing Market Research Report 2022
22 juin 2022 06h53 HE
|
Research and Markets
Dublin, June 22, 2022 (GLOBE NEWSWIRE) -- The "Global MRD Testing Market: Focus on Technology, Application, End User, Region - Analysis and Forecast, 2022-2027" report has been added to...
Persbericht Biocartis Group NV: Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso®
22 juin 2022 01h00 HE
|
Biocartis NV
PERSBERICHT: 22 juni 2022, 07:00 CEST Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso® Mechelen, België,...
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
22 juin 2022 01h00 HE
|
Biocartis NV
PRESS RELEASE: 22 June 2022, 07:00 CEST Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Mechelen, Belgium, 22 June...
Global Diagnostics Partnering Deals Analysis 2015-2022: Analysis of How and Why Companies Enter Diagnostics Partnering Deals
13 juin 2022 04h23 HE
|
Research and Markets
Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Global Diagnostics Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diagnostics...